Cariprazine (Reagila®)

Assessment Status Rapid Review complete
Drug Cariprazine
Brand Reagila®
Indication For the treatment of schizophrenia in adult patients.
Assessment Process
Rapid review commissioned 27/11/2018
Rapid review completed 19/12/2018
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cariprazine (Reagila®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations; June 2019